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Abstract
Background: Serum alkaline phosphatase (ALP) is related to vascular calciﬁcation and is known to have a prognostic impact in
various cohorts. However, evidence in patients undergoing thoracic endovascular aortic repair (TEVAR) is lacking. Thus, we
hypothesized that preoperative serum ALP level could be used for predicting adverse events after TEVAR.
Methods: We retrospectively reviewed 167 patients who underwent TEVAR between February 2013 and December 2016.
Patients were classiﬁed into tertiles according to preoperative ALP level (<69, 69–92, and>92 IU/L). The composite of morbidity and
mortality (composite MM) was deﬁned as the presence of one or more of the following: myocardial infarction, cerebrovascular
accident, dialysis requirement, pulmonary complication, infection, and mortality within 1 year after TEVAR. The incidence of
composite MM was compared among the 3 tertiles, and stepwise logistic regression analysis was performed to evaluate the
predictors for composite MM.
Results: The incidence of composite MM was 14.5% in the ﬁrst tertile group, 17.9% in the second tertile group, and 35.7% in the
third tertile group (P= .016). The third tertile of ALP level (odds ratio [OR] 1.766, 95% conﬁdence interval [CI] 1.074–2.904, P= .025)
and emergency TEVAR (OR 2.369, 95% CI 1.050–5.346, P= .038) remained as independent predictors of composite MM.
Conclusions: Our data showed an independent relationship between high preoperative ALP levels and adverse outcomes in
patients undergoing TEVAR. This ﬁnding might suggest a potential role of ALP level as a risk stratiﬁcation marker.
Abbreviations: AKI = acute kidney injury, ALP = alkaline phosphatase, ALT = alanine aminotransaminase, aneurysm = aortic
aneurysm, AST = aspartate aminotransaminase, BB = b-blocker, BMI = body mass index, CAOD = coronary artery occlusive
disease, CCB = calcium channel blocker, CI = conﬁdence interval, CKD = chronic kidney disease, COPD = chronic obstructive
pulmonary disease, composite MM = composite of morbidity and mortality, Cr = serum creatinine, CRP = C-reactive protein, CSF
drainage = cerebrospinal ﬂuid drainage, CVA = cerebrovascular accident, diabetes = diabetes mellitus, dissection = aortic
dissection, EF = ejection fraction, HTN = hypertension, ICU = intensive care unit, IMH = intramural hematoma, MI = myocardial
infarction, OR = odds ratio, PAU = penetrating aortic ulcer, PCI = percutaneous coronary intervention, POD = duration of
postoperative days in hospital stay, RASi = renin–angiotensin system blocker, TEVAR = thoracic endovascular aortic repair, TNALP
= tissue-nonspeciﬁc isozyme of ALP.
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The development of complications is considered to be much less
frequent after thoracic endovascular aortic repair (TEVAR) than
after open surgery. However, potential pitfalls may exist in
TEVAR given that it is a vascular procedure and the patient
cohort is rarely free from comorbidities. There are a few
reports on risk stratiﬁcations for perioperative cerebral infarction
or 30-day cardiac and cerebrovascular adverse events after
TEVAR.[1,2] Previously identiﬁed risk factors such as a history of
ischemic heart disease and stroke, severe atherosclerosis,
emergency operation, and elevated serum creatinine level are
nonspeciﬁc and prevalent. Furthermore, evidence on the
prognosis for a more prolonged period than the perioperative
course after TEVAR is lacking.
Among the 4 isoforms of alkaline phosphatase (ALP), tissue-
nonspeciﬁc isozyme of ALP (TNALP) has a pivotal role in bone
mineralization.[3] It promotes vascular calciﬁcation by reducing
pyrophosphate, which is a potent inhibitor of medial vascular
mineralization.[4] In addition, its modulatory effect on the
immune system has been implicated in the association between
ALP activity and inﬂammation.[3,5–7] Accordingly, the activity of
TNALP has been reported to regulate the atherosclerotic
process.[8] Serum ALP level mainly reﬂects TNALP[5] and shows
a strong predictability for poor mid-term and long-term
prognosis in patients with kidney disease,[9,10] old age,[11]
myocardial infarction (MI),[12] and stroke,[13,14] as well as in
the general population.[15] In patients undergoing percutaneous
coronary intervention (PCI), elevated serum ALP level is closely
associated with a higher risk of adverse cardiac and cerebrovas-
cular events,[16] or mortality and stent thrombosis.[17] Consider-
ing that aortic disease requiring intervention may be closely
related to the calciﬁcation and inﬂammation of the vascula-
ture,[18,19] ALP might have a potential role as a prognostic
marker in patients undergoing TEVAR, which has never been
investigated before.
Hence, we aimed to investigate whether preoperative serum
ALP level could be used for predicting adverse events after
TEVAR.2. Methods
2.1. Study population
After receiving approval and waiver of the informed consent
requirement from our institutional review board, we retrospec-
tively reviewed the electronic medical records of all patients who
underwent TEVAR of the aortic arch and descending aortic
lesions at our university hospital between January 2013 and
December 2016 (n=197). Patients with traumatic aortic injury
(n=28), preoperative cardiopulmonary resuscitation (n=1), or
previous aortic repair within 1 year (n=1) were excluded.
Finally, 167 patients were analyzed. To assess risk of
postoperative morbidity according to the preoperative serum
ALP, we divided patients into 3 groups based on its level (ﬁrst
tertile: ALP <69IU/L [n=55], second tertile: ALP 69–92IU/L,
[n=56], third tertile: ALP >92IU/L [n=56]).2.2. TEVAR procedure
TEVAR was performed in a hybrid operating room equipped
with angiographic systems. Stent graft including Valiant
(Medtronic Vascular, Santa Rosa, CA), Vascutek (Terumo;2Renfrewshire, Scotland, UK), TAG (W.L. Gore and Associates,
Flagstaff, AZ), and Zenith TX1/TX2 (Cook Medical, Bloo-
mington, IN) were used. In patients with zone 0, zone 1, or zone 2
landing TEVAR, multiple chimneys or fenestrated endografts
were used for debranching. Moreover, in patients undergoing
debranching, cerebral regional oxygen saturation was monitored
andmaintained within 20% of baseline during clamping of vessel
by increasing blood pressure and end-tidal carbon dioxide. In
patients with landing zone of 3 or 4 that endograft covers T9 to
T12, cerebrospinal drainage was performed and spinal cord
perfusion pressure was maintained at >60mm Hg. Systolic
arterial pressure was maintained at <100mm Hg before stent
deployment. Furthermore, after deploying the stent, systolic
arterial pressure was maintained at >140mm Hg using volume
replacement and nicardipine or norepinephrine, as appropriate.
All patients were extubated in the operating room except those
with oxygen desaturation or signiﬁcant hemodynamic instability
and transported to the intensive care unit.2.3. Study endpoints
The primary outcome was the incidence of newly developed MI,
stroke, dialysis requirement, infection, pulmonary complication,
mortality, and a composite (1 or more) of these endpoints within
1 year after TEVAR.MI was deﬁned as an increase in serum peak
troponin-T isozyme >5 times the upper limit of normal or a
newly developed Q wave. Stroke was deﬁned as the presence of
newly developed neurological deterioration induced by embolic,
thrombotic, or hemorrhagic brain injury diagnosed by a
neurologist. Infection was deﬁned as the occurrence of 1 of the
following conditions: pneumonia, sepsis, peritonitis, urinary
tract infection, or graft infection. Pulmonary complication was
deﬁned as respiratory failure, exacerbation of chronic obstructive
disease, or culture-negative pneumonia that required prolonged
mechanical ventilation (>24hours).2.4. Other assessments
Baseline patient characteristics including sex; age; body mass
index; comorbidities (hypertension, diabetes mellitus, coronary
artery occlusive disease [CAOD], chronic obstructive pulmonary
disease, cerebrovascular accident, and chronic kidney disease);
preoperative cardiovascular medication; disease acuity; smoking;
presence of malperfusion, deﬁned as signs or symptoms of end-
organ ischemia; preoperative ejection fraction; and preoperative
laboratory data including C-reactive protein (CRP), creatinine,
aspartate aminotransaminase, and alanine aminotransaminase
levels were recorded. Perioperative data including the proximal
landing zone classiﬁed according to Ishimaru classiﬁcation,
spinal drainage, and total procedure time were recorded.2.5. Statistical analysis
All statistical analyses were performed using SPSS version 23
(IBM Corp, Armonk, NY). After the Shapiro–Wilk test for
normality, one-way analysis of variance or Kruskal–Wallis test
was used to compare continuous variables, as appropriate.
Categorical variables were compared using the chi-squared or
Fisher exact test. Results are presented as mean± standard
deviation or number of patients (%). Logistic regression analysis
to evaluate the predictors for 1-year composite of morbidity and
mortality (composite MM) endpoints was conducted on
Ham et al. Medicine (2019) 98:38 www.md-journal.comvariables with P< .2 between patients who developed the
composite endpoint of morbidity and mortality. For the
multivariate analysis, a stepwise selection method was used
and variables with P< .2 in the univariate analysis were selected.
Predictability was expressed as the odds ratio (OR) and 95%
conﬁdence interval (CI). Values of P< .05 were considered
statistically signiﬁcant.3. Results
A total of 197 patients were identiﬁed during the study period
and 167 patients were ﬁnally analyzed. Baseline characteristics
were comparable among the groups (Table 1).
Table 2 shows the perioperative data including operative
details and immediate postoperative data. The number of patients
with proximal landing zone of 0 was signiﬁcantly different
among the 3 groups (0% vs. 1.8% vs. 8.9%, P= .048). Combined
procedure including head-vessel debranching and cerebrospinal
ﬂuid drainage, operation time, immediate postoperative endo-
leak, acute kidney injury, and postoperative lengths of stay in the
intensive care unit and in the hospital were similar among the
groups.
Each of the postoperative 1-year morbidity endpoints showed
no difference among the groups; however, there was a trend
toward a higher incidence of pulmonary complication in the third
tertile. The incidence of the composite MM was signiﬁcantly
higher in the third tertile than in the lower 2 tertiles (14.5% vs.
17.9% vs. 35.7%, P= .016) (Table 3).Table 1
Baseline characteristics.
First tertile (n=55) Second
Female sex 16 (29.1%) 1
Age (years) 62.02±15.05 63
Height (cm) 165.01±9.95 16
Weight (kg) 67.11±13.36 69
BMI 24.45±3.05 2
HTN 42 (76.4%) 4
DM 7 (12.7%)
CAOD 2 (3.6%)
COPD 0
CVA 6 (10.9%)
CKD 3 (5.5%)
BB 16 (30.2%) 1
CCB 18 (34.0%) 2
RASi 22 (41.5%) 2
Emergency operation 20 (36.4%) 1
Smoking 23 (41.8%) 3
Preoperative EF 63.52±5.67 6
Primary aortic disease
Aneurysm 23 (41.8%) 2
Dissection 21 (38.2%) 2
IMH/PAU 11 (20.0%) 1
Malperfusion 2 (3.6%)
Preoperative CRP 23.91±39.33 40
Preoperative Cr 0.89±0.35 1
Preoperative AST 28.13±30.05 25
Preoperative ALT 21.79±18.34 21
Values are presented as mean± standard deviation or number of patients (%).
ALT= alanine aminotransaminase, aneurysm=aortic aneurysm, AST= aspartate aminotransferase, BB=
blocker, CKD= chronic kidney disease, COPD= chronic obstructive pulmonary disease, Cr= serum c
dissection= aortic dissection, EF= ejection fraction, HTN=hypertension, IMH= intramural hematoma, P
3Age, preexisting hypertension, CAOD, chronic kidney disease,
the third ALP tertile, combined head-vessel debranching,
presence of malperfusion, and emergency operation showed a
difference of P< .2 between patients who developed the
composite endpoint and those who did not, and were analyzed
using logistic regression. In univariate analysis, hypertension,
CAOD, the third ALP tertile, malperfusion, and emergency
operation were selected for multivariate analysis. The third ALP
tertile (OR 1.766, 95%CI 1.074–2.904, P= .025) and emergency
operation (OR 2.369, 95% CI 1.050–5.346, P= .038) remained
independent predictors for the composite endpoint of morbidity
and mortality (Table 4).4. Discussion
In this retrospective study investigating the association of serum
ALP level with 1-year adverse outcomes after TEVAR, the
incidence of the composite endpoints of MI, stroke, dialysis
requirement, infection, pulmonary complication, and mortality
were signiﬁcantly higher in patients with the third tertile
distribution of ALP than in those in the lower 2 tertiles.
Moreover, the third tertile of ALP was independently associated
with a 1.8-fold increased risk for developing the composite of
morbidity endpoints.
Among the 4 isoforms of ALP in humans, TNALP, which is
mainly found in the liver and bone, stimulates tissue mineraliza-
tion.[3] Its overexpression in the vasculature is known to induce
coronary and aortic calciﬁcation, cardiac hypertrophy, andtertile (n=56) Third tertile (n=56) P
4 (25.0%) 17 (30.4%) .805
.55±14.60 64.38±12.90 .676
7.17±9.77 165.08±7.66 .377
.73±13.00 64.93±11.60 .136
4.83±3.35 23.74±3.36 .200
1 (73.2%) 41 (74.5%) .929
5 (8.9%) 5 (9.1%) .758
5 (8.9%) 4 (7.1%) .629
1 (1.8%) 1 (1.8%) 1.000
7 (12.5%) 4 (7.1%) .629
6 (10.9%) 2 (3.6%) .284
8 (34.0%) 17 (30.9%) .906
2 (41.5%) 19 (34.5%) .667
7 (50.9%) 22 (40.0%) .466
9 (33.9%) 29 (51.8%) .114
4 (60.7%) 30 (54.5%) .127
4.72±5.78 61.28±15.34 .416
3 (41.1%) 18 (32.1%) .505
3 (41.1%) 25 (44.6%) .787
0 (17.9%) 13 (23.2%) .778
5 (8.9%) 2 (3.6%) .512
.90±62.10 48.37±75.71 .158
.00±0.45 0.94±0.71 .582
.02±11.36 33.07±23.48 .175
.89±14.44 27.82±28.24 .233
b-blocker, BMI=body mass index, CAOD= coronary artery occlusive disease, CCB= calcium channel
reatinine, CRP=C-reactive protein, CVA= cerebrovascular accident, diabetes=diabetes mellitus,
AU=penetrating aortic ulcer, RASi= renin–angiotensin system blocker.
Table 2
Perioperative data.
First tertile (n=55) Second tertile (n=56) Third tertile (n=56) P
Proximal landing zone
0 0 1 (1.8%) 5 (8.9%) .048
∗
1 5 (9.1%) 4 (7.1%) 2 (3.6%) .467
2 25 (45.5%) 30 (53.6%) 26 (46.4%) .645
3 22 (40.0%) 14 (25.0%) 14 (25.0%) .138
4 18 (32.7%) 19 (33.9%) 15 (26.8%) .683
Debranching surgery 14 (25.5%) 18 (32.1%) 16 (28.6%) .738
CSF drainage 31 (56.4%) 36 (64.3%) 26 (46.4%) .163
Operation time 119.40±92.27 119.02±77.13 130.25±107.16 .769
Immediate endoleak 6 (10.9%) 5 (8.9%) 6 (10.7%) .930
AKI 14 (25.5%) 17 (30.4%) 16 (28.6%) .845
ICU stay (hour) 74.75±212.81 42.51±95.57 68.67±122.84 .493
POD 14.89±30.19 11.04±9.90 19.11±26.67 .206
Values are presented as the mean± standard deviation, or number of patients (%).
AKI= acute kidney injury, CSF drainage= cerebrospinal ﬂuid drainage, ICU= intensive care unit, POD=duration of postoperative days in hospital stay.
∗
P< .05.
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the activity of TNALP and can be indicative of vascular
calciﬁcation.[22] In this context, higher serum ALP levels have
been implicated in the poor prognosis of patients with kidney
failure whose mineral metabolism is altered.[9,10] The associa-
tions of serum ALP levels with mortality were also demonstrated
in other patient cohorts, including those with previous MI or
stroke, elderly patients, and even in the general population.[11–15]
Along with such a strong predictability for the natural course and
survival of patients with vascular diseases, serum ALP level was
recently shown to have a prognostic potential for post-
interventional adverse events in patients with CAOD undergoingTable 3
Postoperative 1-year morbidity and mortality.
First tertile (n=55) Secon
Myocardial infarction 0
Stroke 2 (3.6%)
Dialysis 3 (5.5%)
Infection 2 (3.6%)
Pulmonary complication 4 (7.3%)
Mortality 5 (9.1%)
Composite 8 (14.5%)
Values are presented as number of patients (%).
∗
P< .05.
Table 4
Logistic regression analysis for predictors of composite endpoints of
repair.
Univariate OR (CI)
Age 1.021 (0.989–1.055)
HTN 2.072 (0.708–6.063)
CAOD 2.808 (0.640–12.329)
CKD 1.147 (0.238–5.528)
ALP third tertile 1.741 (1.049–2.890)
Debranching surgery 1.576 (0.658–3.773)
Malperfusion 3.211 (0.741–13.921)
Emergency 2.217 (0.955–5.148)
Values are presented as odds ratio (95% conﬁdential interval).
ALP=alkaline phosphatase, CAOD= coronary artery occlusive disease, CI= conﬁdence interval, CKD=
4percutaneous revascularization.[16,17] Consistent with this, we
observed a signiﬁcant relationship between the preoperative
serum ALP level and poor clinical outcomes in patients with
aortic disease undergoing TEVAR. Considering that the bone–
vascular axis might be also perturbed in aortic disease,[18,19,23]
our ﬁnding can be, at least partly, attributable to complications
caused by ill-fated vasculature associated with calciﬁcation, as in
patients with renal and cardiovascular disease.
The literature shows a signiﬁcant relationship between ALP
level and clinical outcomes based on calciﬁcation of vascular
smooth muscle cells or endothelial cells, which are mainly
involved in cardiac and brain vascular health.[3] However,d tertile (n=56) Third tertile (n=56) P
0 3 (5.4%) .107
4 (7.1%) 6 (10.7%) .398
1 (1.8%) 5 (8.9%) .249
2 (3.6%) 3 (5.4%) 1.000
3 (5.4%) 10 (17.9%) .063
3 (5.4%) 5 (8.9%) .769
10 (17.9%) 20 (35.7%) .016
∗
1-year morbidity and mortality after thoracic endovascular aortic
P Multivariate OR (CI) P
.204
.184 2.274 (0.818–6.323) .115
.171 3.111 (0.742–13.050) .121
.864
.032 1.766 (1.074–2.904) .025
.307
.119 3.177 (0.758–13.319) .114
.064 2.369 (1.050–5.346) .038
chronic kidney disease, HTN=hypertension, OR=odds ratio.
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Other vascular cells of mesenchymal origin, including pericytes
and ﬁbroblasts, can also undergo osteochondrogenic transfor-
mation induced by ALP activity.[24] Hence, we evaluated multiple
clinical endpoints instead of only cardiac and cerebrovascular
morbidity, unlike in previous studies.
The higher burden of systemic inﬂammatory status that was
reported to be associated with elevated ALP activity could trigger
the development of end-organ disease.[3,12,14] Furthermore, ALP
has been reported to be associated with CRP, which reﬂects
inﬂammation.[7,25] In addition to the involvement of vascular
cells, increased activity of TNALP in leukocytes has been
implicated in higher serum ALP levels in sepsis and other acute
inﬂammatory conditions.[6] Particularly, B-cell activity, which is
known to be strongly inﬂuenced by factors regulating osteoblasts
and osteoclasts, may play an important role.[5] Accordingly,
increased serum ALP level is considered a cellular response to
inﬂammatory stimuli such as bacterial invasion.[3] In this regard,
there are several reports on the association of higher serum ALP
level and infection-related death both in patients undergoing
dialysis[26] and in those with normal renal function.[27] Our
ﬁnding of a close relationship between ALP level and the
composite of endpoints could also be at least partly attributable
to infection and sepsis-related mortality, although there was no
signiﬁcant association of ALP level and infection per se. The exact
pathophysiologic mechanisms of the interplay between ALP level
and susceptibility to infection are not known; however, increased
expression of ALP induced by pathogens was reported to trigger
the Toll-like receptor 4/nuclear factor-kB pathway, resulting in
the production of pro and anti-inﬂammatory cytokines.[3,28] In
this regard, whether ALP activates or inhibits the inﬂammatory
reaction should be postulated cautiously through further
investigations. The conﬂicting evidences about ALP level and
renal outcomes should be considered in the same context. A
renoprotective action of ALP through reduced inﬂammation and
oxidative stress was reported,[3,6,29] whereas a strong association
was found between higher ALP level and poor prognosis in
patients with kidney disease.[9,10,20,26] Our analysis revealing a
biphasic relationship between the ALP tertiles and dialysis
requirement, despite the lack of statistical signiﬁcance, may be
explained in this context.
Among the outcomes of our analysis, pulmonary complication
was the most closely linked factor to ALP level, although it did
not reach statistical signiﬁcance (P= .063). In accordance with
our result, a previous report observed that serum ALP level
returned to normal according to the cure of the lung
pathology.[30] Moreover, several studies reported serum ALP
level as a diagnostic marker in various pulmonary diseases such
as chronic interstitial lung disease and idiopathic pulmonary
ﬁbrosis.[31–33] Calciﬁcation of endothelial cells, pericytes, and
ﬁbroblasts in the alveolar-capillary structure and bronchial tree
could have induced respiratory failure, exacerbation of chronic
obstructive disease, or pneumonia in our patients. The higher
grade of inﬂammation in patients with elevated ALP levels could
also involve the lung parenchyma, alveolar capillary unit, and
airways, leading to adverse clinical events.[7]
The role of serum ALP level as a prognostic factor for adverse
outcomes has been demonstrated in various cohorts. Serum ALP
level was reported to be associatedwith coronary disease and also
with increased mortality in elderly men.[11] In a recent study
conducted in patients after PCI, higher serum ALP levels
predicted mortality, MI, and stent thrombosis.[17] In addition,5elevated serum ALP level was found to be an independent risk
factor of major adverse cardiac or cerebrovascular events after
primary PCI in patients with ST-segment elevation MI.[16]
However, serum ALP level did not have a prognostic value for
predicting adverse outcomes such as major adverse cardiac
events, mortality, MI, or revascularization after off-pump
coronary artery bypass surgery.[34] This discrepancy may be
due to the different inﬂammatory process between PCI and open
cardiac surgery. As serum ALP level was reported to reﬂect
inﬂammation, a different inﬂammatory process may be an
important factor for predicting adverse outcomes by using serum
ALP level. Considering that serum ALP level reﬂects inﬂamma-
tion and vascular calciﬁcation, this parameter could be expected
to have a prognostic value for predicting adverse outcomes after
TEVAR. We ﬁrst demonstrated that the occurrence of 1 or more
amongMI, stroke, dialysis, infection, and mortality within 1 year
after TEVAR can be strongly predicted by high preoperative
serum ALP levels, which is the strength of the present study.
This study has several limitations. First, the small sample size
may reduce validity and reliability of the current result. Lack of
signiﬁcant differences in the risk of each morbidity endpoints
among the groups could also be attributable to small sample size.
Second, incomplete adjustment of the confounding factors can
also be a threat to reliability of the result. We observed no
differences in the preoperative liver enzymes and pre-existing
renal insufﬁciency which are closely related to ALP level among
the groups. However, other factors that can affect the result, such
as bone disease, malnutrition, or infection, were not included in
analysis because of our insufﬁcient dataset, which makes
possibility of consequent bias cannot be excluded. Similarly, a
greater portion of patients had proximal landing zone 0 in the
third tertile group. Although the primary outcome was not
different according to the proximal landing zone, the difference
among the groups could at least partly confound the result.
Further studies on larger sample size and a thorough control of
confounders should be conducted to get more conclusive results.
In conclusion, serum ALP level was independently associated
with an increased risk of a composite MM during 1 year after
TEVAR, along with emergency operation. This result suggests
that serum ALP level has a prognostic value for adverse outcomes
after TEVAR, and that the possible mechanisms for this
prognostic effect might be associated with inﬂammation and
vascular calciﬁcation; however, this needs to be clariﬁed in
further investigations.Author contributions
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